Staff Science & Health Desk | MENLO PARK, CALIFORNIA
A Vial of Blood Against the Deadliest Disease in Medicine
Somewhere in a lab outside Menlo Park, a machine reads the genetic wreckage floating in a tube of human blood, hunting for chemical fingerprints of cancers that haven't announced themselves yet. No lump. No cough. No weight loss. Just fragments of DNA, shed by dying cells, drifting through the bloodstream long before a tumor is big enough to feel, see, or scan for.
That's the pitch behind Galleri, the multi-cancer early detection test built by GRAIL—and it's no longer just a pitch. On January 29, 2026, GRAIL filed the final module of its Premarket Approval application with the FDA. NPR reported on June 21 that a decision could land before year's end, setting up Medicare coverage as early as 2028 after Congress already voted to allow reimbursement for multi-cancer detection tests starting that year.
The premise sounds almost too clean: one blood draw, fifty types of cancer, caught before stage IV turns a treatable disease into a death sentence. Cancer remains the second-leading cause of death in the U.S., and survival rates for almost every major cancer fall off a cliff once the disease reaches a late stage. If a single test could reliably catch tumors while still small, confined, and operable, it would be one of the most consequential advances in preventive medicine.
The question now sitting on the FDA's desk—and increasingly in doctors' offices—is whether Galleri actually delivers on that promise, or whether the excitement has outrun the evidence.
Inside the Data: What the World's Biggest Cancer-Screening Trial Found
The numbers come from two enormous studies, unlike anything cancer screening has seen before. The NHS-Galleri trial enrolled more than 142,250 volunteers aged 50 to 77 across England's NHS—the first and only randomized, controlled trial ever conducted of a multi-cancer early detection test, run over three annual screening rounds. In North America, GRAIL's PATHFINDER 2 study added another 25,490 participants.
Full results from the NHS trial, unveiled at the 2026 ASCO annual meeting, reported a striking finding: a substantial reduction in stage IV cancer diagnoses among people screened annually with Galleri, alongside increased detection of stage I and II cancers for some of the most lethal tumor types, and a four-fold higher overall cancer detection rate compared with the unscreened control group. There were no serious test-related adverse events.
Across the three screening rounds, 1,801 participants—0.91% of the trial population—received a positive cancer-signal result. Of those, 937 were ultimately diagnosed with cancer, for an overall detection rate of 0.48%. The test's positive predictive value—the odds that a positive result actually corresponds to real cancer—came in at 52.0% overall and 58.0% in the first round. Researchers consider that remarkably high for a screening tool covering dozens of cancer types simultaneously, several of which (pancreatic, ovarian, liver, esophageal) have no standalone screening test at all today.
For patients with cancers that are otherwise silent until it's too late, that detail matters enormously. A test that flags even a fraction of pancreatic or ovarian cancers at an operable stage could save lives that current screening simply cannot.
The Catch Nobody Wants to Put on the Billboard
But the same dataset contains the test's weak spots—significant enough that some oncologists are urging caution before the public treats Galleri as a guarantee.
The test's overall sensitivity—its ability to catch a cancer that is present—sits at roughly 51.5%, meaning it misses essentially half of all cancers it screens for. That average conceals a steep stage-by-stage drop-off: Galleri detects only about 16.8% of stage I cancers—the very early tumors where intervention matters most—rising to 40.4% for stage II, 77.0% for stage III, and 90.1% for stage IV, by which point many other forms of detection are already in play. In plain terms, the test is good at finding cancer once it's advanced and far less reliable at catching it in the early window where early detection is supposed to deliver its biggest benefit.
False positives carry their own cost. In PATHFINDER, roughly 1.4% tested positive, but a striking 62% of those positive results turned out not to correspond to any cancer—meaning a meaningful share of healthy people are funneled into follow-up scans, biopsies, and weeks of anxiety chasing a signal that was never there. The test also missed a substantial share of cancers diagnosed within a year of a negative result, raising a related worry: that a clean Galleri result might give patients and even physicians false reassurance, encouraging some to skip other screenings.
None of this makes Galleri useless—specificity remains high at 99.5%, which is precisely why the positive predictive value can stay strong even with imperfect sensitivity. But it does mean the test is a powerful supplement to existing screening, not a replacement—a distinction that gets lost fast in marketing copy and dinner-table conversation.
The FDA's Moment of Truth—and the Competition Lining Up Behind It
Galleri isn't entering a regulatory vacuum. The test has been commercially available since 2021 as a laboratory-developed test, ordered through a physician and paid out of pocket, with more than 475,000 tests sold to date. Competitors are closing in fast: Abbott presented new data on its Cancerguard program at the AACR's 2026 annual meeting in April, signaling that whichever way the FDA rules on Galleri, this is now a multi-company race.
What FDA approval changes is scale. A PMA approval would let Galleri be marketed as an approved medical device rather than a lab-developed workaround, and crucially, it would unlock the Medicare reimbursement pathway Congress has already authorized for 2028. For a test that costs hundreds of dollars out of pocket today, insurance coverage is the difference between a screening tool for the affluent and one available to tens of millions of Americans over 50.
What Doctors Are Actually Saying
Oncologists reviewing the data have been measured rather than euphoric. Coverage framed the stage-shift findings—fewer stage IV diagnoses, more early-stage catches for the deadliest cancer types—as the most clinically meaningful result, precisely because shifting diagnosis earlier is what actually changes survival odds. At the same time, watchdog groups including FORCE have published explicit pushback under headlines like "Headline Hype: One simple blood test to detect 50 cancers? Not yet," arguing that sensitivity gaps and false positives mean the test is not yet the panacea the marketing implies.
That tension—genuine, trial-validated benefit alongside genuine, trial-validated limitations—is exactly the kind of nuance that tends to get flattened once a product reaches pharmacy shelves and insurance riders.
What This Means for You
If you're over 50, the realistic takeaway is this: the test is a meaningful, evidence-backed addition to cancer screening, not a substitute for the mammograms, colonoscopies, and Pap smears your doctor already recommends. A negative Galleri result is not a clean bill of health, especially for early-stage disease, where sensitivity is weakest. A positive result is worth taking seriously—the 52-58% positive predictive value is unusually strong for a screening test—but it is also not a diagnosis, and a meaningful share of positives will be false alarms requiring follow-up.
If FDA approval arrives by year's end, the practical change for most people won't be availability—the test has been purchasable since 2021—but cost and credibility: insurance coverage starting in 2028 would put it within reach of far more households.
The Bottom Line
Cancer screening has spent decades built around single-organ tests—one for breast, one for colon, one for cervix—leaving rarer, harder-to-catch cancers with no early-warning system at all. Galleri is the first test to seriously challenge that model at population scale, and the NHS-Galleri trial is the strongest evidence yet that a single blood draw can meaningfully shift diagnoses toward earlier, more survivable stages. But "meaningful shift" is not "solved problem." With sensitivity for early-stage cancers still under 50%, and roughly six in ten asymptomatic positive results turning out to be false alarms, the test arrives at the FDA's door as a genuine medical advance wrapped in real, unresolved trade-offs. The agency's ruling, expected before the year is out, won't settle the scientific debate—but it will determine how many Americans get to have that debate with their own doctor instead of just reading about it.
